Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25808542 | 1.00 | MTNR1A (0.44) | MTNR1AMTNR1BNAMPTDRD2DRD3 | |
| SCHEMBL8136269 | 0.90 | MTNR1A (0.45) | MTNR1AMTNR1BNAMPTCACNA1HNPSR1 | |
| SCHEMBL14155724 | 0.89 | CCR3 (0.44) | MTNR1AMTNR1BCACNA1HNPSR1MAPT | |
| SCHEMBL14559366 | 0.89 | CCR3 (0.44) | MTNR1AMTNR1BCACNA1HNPSR1MAPT | |
| SCHEMBL17207607 | 0.89 | CCR3 (0.44) | MTNR1AMTNR1BCACNA1HNPSR1MAPT | |
| SCHEMBL3937928 | 0.87 | NAMPT (0.42) | NAMPTDRD2DRD3MAPTSSTR4 | |
| SCHEMBL15841168 | 0.86 | MTNR1A (0.47) | MTNR1AMTNR1BCACNA1HNPSR1MAPK1 | |
| SCHEMBL31420630 | 0.85 | CYP2D6 (0.44) | NAMPTDRD2DRD3MAPTSSTR4 | |
| SCHEMBL856649 | 0.85 | CYP2D6 (0.44) | NAMPTDRD2DRD3MAPTSSTR4 | |
| SCHEMBL12136889 | 0.81 | EPHX2 (0.48) | MTNR1AMTNR1BCACNA1HNPSR1CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3958867-B1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2022166920-A1 | PYRROLOPYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150087043-A1 | MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION THAT EMPLOY BIOORTHOGONAL CHEMISTRIES, AND METHODS OF USING SAME | Coferon, Inc (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150080570-A1 | ALPHA,BETA-UNSATURATED MONOMERS CAPABLE OF MULTIMERIZATION IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1613634-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087714-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | MTNR1A 1495/4885MTNR1B 2222/4885NAMPT 45/4885 |
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | MTNR1A 4563/4885MTNR1B 4639/4885NAMPT 2993/4885 |
| US-20150080570-A1 | ALPHA,BETA-UNSATURATED MONOMERS CAPABLE OF MULTIMERIZATION IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | FABP1, TTPA, STIM1 | MTNR1A 1972/4885MTNR1B 2509/4885NAMPT 2661/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | MTNR1A 4563/4885MTNR1B 4639/4885NAMPT 2993/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | MTNR1A 200/4885MTNR1B 115/4885NAMPT 349/4885 |
| US-20150087043-A1 | MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION THAT EMPLOY BIOORTHOGONAL CHEMISTRIES, AND METHODS OF USING SAME | ECPAS, CALCOCO2, MDN1 | MTNR1A 2860/4885MTNR1B 2990/4885NAMPT 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.